神经病理性疼痛
医学
大麻酚
神经保护
大麻素
神经损伤
神经痛
药理学
慢性疼痛
神经科学
麻醉
大麻
内科学
物理疗法
受体
精神科
生物
作者
Peggy Arthur,Anil Kumar Kalvala,Sunil Kumar Surapaneni,Mandip Singh
出处
期刊:Critical Reviews in Therapeutic Drug Carrier Systems
[Begell House Inc.]
日期:2024-01-01
卷期号:41 (1): 1-33
标识
DOI:10.1615/critrevtherdrugcarriersyst.2022038592
摘要
Neuropathic pain is experienced due to injury to the nerves, underlying disease conditions or toxicity induced by chemotherapeutics. Multiple factors can contribute to neuropathic pain such as central nervous system (CNS)-related autoimmune and metabolic disorders, nerve injury, multiple sclerosis and diabetes. Hence, development of pharmacological interventions to reduce the drawbacks of existing chemotherapeutics and counter neuropathic pain is an urgent unmet clinical need. Cannabinoid treatment has been reported to be beneficial for several disease conditions including neuropathic pain. Cannabinoids act by inhibiting the release of neurotransmitters from presynaptic nerve endings, modulating the excitation of postsynaptic neurons, activating descending inhibitory pain pathways, reducing neural inflammation and oxidative stress and also correcting autophagy defects. This review provides insights on the various preclinical and clinical therapeutic applications of cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) in various diseases and the ongoing clinical trials for the treatment of chronic and acute pain with cannabinoids. Pharmacological and genetic experimental strategies have well demonstrated the potential neuroprotective effects of cannabinoids and also elaborated their mechanism of action for the therapy of neuropathic pain.
科研通智能强力驱动
Strongly Powered by AbleSci AI